• Home
  • Practice Focus
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
    • How I Do It
    • TRIO Best Practices
  • Business of Medicine
    • Health Policy
    • Legal Matters
    • Practice Management
    • Tech Talk
    • AI
  • Literature Reviews
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Career
    • Medical Education
    • Professional Development
    • Resident Focus
  • ENT Perspectives
    • ENT Expressions
    • Everyday Ethics
    • From TRIO
    • The Great Debate
    • Letter From the Editor
    • Rx: Wellness
    • The Voice
    • Viewpoint
  • TRIO Resources
    • Triological Society
    • The Laryngoscope
    • Laryngoscope Investigative Otolaryngology
    • TRIO Combined Sections Meetings
    • COSM
    • Related Otolaryngology Events
  • Search

What Is a Biosimilar?

by Jennifer Fink • August 16, 2017

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version

“One of the things that could affect the market—and this happened in Europe—is that they didn’t do much switching in the beginning,” said Joseph Fuhr, PhD, adjunct professor of pharmaceutical and healthcare business at University of the Sciences in Philadelphia. “What happened was, if a doctor had a new patient, they would put them on the biosimilar but not switch anybody away from the original product.”

You Might Also Like

  • What Is a Biosimilar?
  • What Otolaryngologists Need to Know about Biologics and Allergic Rhinitis
  • Are Biologics Viable Options for Treating Pediatric Illness?
  • Are New Biologics a Game Changer for Treating Nasal Polyposis?
Explore This Issue
August 2017

Dr. Fuhr expects what happened in Europe to happen in the U.S.: Uptake of biosimilars will improve, and costs will go down, when interchangeability is demonstrated.

“When small-molecule generics came out, there was a big outcry and a lot of skepticism,” said Hakim. “What is now an accepted fact in the U.S. medical system is that small-molecule generics are just as good; there’s no reason to be skeptical of them.

“I think the same thing is going to be true for biosimilars. Hopefully, as regulatory bodies and clinicians gain a level of comfort on the basis of rigorous scientific and clinical data, we’ll be able to use biosimilars with the same degree of comfort as we use small-molecule generics.”


Jennifer Fink is a freelance medical writer based in Wisconsin.

Take-Home Points

  • Biologics and biosimilars may soon become important therapeutic options in all areas of medicine, including otolaryngology.
  • Minor differences in manufacturing, processing, and packaging may result in meaningful differences in both biosimilars and the originator biologics.
  • Biologics are relatively new within the field of otolaryngology, and no biosimilars have been FDA approved for otolaryngologic indications.
  • Biosimilar use in otolaryngology likely will occur in the treatment of allergy, immunology, and chronic rhinosinusitis.

Hospitalists as Test Subjects

According to a 2014 study by the RAND Corporation, biosimilars will “lead to a $44.2 billion reduction in direct spending on biologic drugs from 2014 to 2024” (2017. Rand.org). In Europe, biosimilars typically cost at least 25% less than reference biologics. Will the United States see similar savings?

Maybe. “The federal approval of the first biosimilar in the U.S. was supposed to foster the development of new products that offered big discounts on some of healthcare’s most expensive treatments,” said Dr. Das. “But there’s been no flood of new drugs and no lower prices since the FDA’s approval of Zarxio.”

One key to potential savings will be the FDA requirements for interchangeability. If the FDA requires extensive, expensive clinical testing to prove interchangeability, cost savings may not be as significant as anticipated.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Features, Home Slider Tagged With: biologic drugs, biologics, biosimilar, otolaryngology, pharmaceuticalsIssue: August 2017

You Might Also Like:

  • What Is a Biosimilar?
  • What Otolaryngologists Need to Know about Biologics and Allergic Rhinitis
  • Are Biologics Viable Options for Treating Pediatric Illness?
  • Are New Biologics a Game Changer for Treating Nasal Polyposis?

The Triological SocietyENTtoday is a publication of The Triological Society.

Polls

Would you choose a concierge physician as your PCP?

View Results

Loading ... Loading ...
  • Polls Archive

Top Articles for Residents

  • Applications Open for Resident Members of ENTtoday Edit Board
  • How To Provide Helpful Feedback To Residents
  • Call for Resident Bowl Questions
  • New Standardized Otolaryngology Curriculum Launching July 1 Should Be Valuable Resource For Physicians Around The World
  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment

    • Keeping Watch for Skin Cancers on the Head and Neck

    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?

    • Otolaryngologists Are Still Debating the Effectiveness of Tongue Tie Treatment

    • Is Middle Ear Pressure Affected by Continuous Positive Airway Pressure Use?

    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment

    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?

    • Is Middle Ear Pressure Affected by Continuous Positive Airway Pressure Use?

    • Otolaryngologists Are Still Debating the Effectiveness of Tongue Tie Treatment

    • Complications for When Physicians Change a Maiden Name

    • Excitement Around Gene Therapy for Hearing Restoration
    • “Small” Acts of Kindness
    • How To: Endoscopic Total Maxillectomy Without Facial Skin Incision
    • Science Communities Must Speak Out When Policies Threaten Health and Safety
    • Observation Most Cost-Effective in Addressing AECRS in Absence of Bacterial Infection

Follow Us

  • Contact Us
  • About Us
  • Advertise
  • The Triological Society
  • The Laryngoscope
  • Laryngoscope Investigative Otolaryngology
  • Privacy Policy
  • Terms of Use
  • Cookies

Wiley

Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1559-4939